US › Healthcare

Arvinas Inc (ARVN)

US · Healthcare · Biotechnology

$9.00+11.66%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$15.6M

Revenue YoY

-91.7%

Net profit

$-57.6M

Profit YoY

-169.5%

EPS

$-0.90

EPS estimate

$-0.96

Net margin

-369.2%

EPS came in at -0.90 against a street estimate of -0.96 — a beat of 6.6%.

Key statistics

Market cap

$520.0M

Forward P/E

17.9

P/B

1.34

Book value

$6.00

EPS (TTM)

$-3.18

52-week high

$14.51

52-week low

$6.05

50-day MA

$8.13

200-day MA

$10.64

Beta

1.74

Analyst view

Analysts rate Arvinas Inc a buy (13 buy, 8 hold, 0 sell out of 21) with an average price target of $14.79.

Shareholding

Insiders

7.91%

Institutions

82.15%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.54%
Vanguard Portfolio Management, LLC	6.03%
D. E. Shaw & Co LP	5.64%
Pfizer Inc	5.36%
Vanguard Capital Management, LLC	4.17%
TCG Crossover Management, LLC	3.70%
Armistice Capital, LLC	3.07%
Two Sigma Investments LLC	2.84%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arvinas Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.